Sam Brusco, Associate Editor08.18.23
IMIDEX, a company focused on developing artificial intelligence (AI)-based lung cancer solutions, earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its flagship VisiRad XR AI-powered software, which analyzes chest X-rays and highlights potential lung nodules and masses.
The software uses machine learning techniques and was developed using global, curated training data. It allows clinicians a closer look at lung lesions that are often overlooked to help identify future lung cancers in outpatient and emergency care settings.
“Radiologists are looking for solutions to help elevate their performance and reduce burnout,” Dr. Raj Chopra, chief medical officer of IMIDEX told the press. “With volumes increasing and staffing decreasing, tools like VisiRad XR are beneficial not only for patient care, but for helping radiologists continue to practice to their full potential.”
The turnkey VisiRad XR tool plugs into current radiology workflows, routing images with AI-detected lesions back to radiologists in their native viewing environment. Results can be seen directly behind the image for interpretation. VisiRad XR’s aim is to increase the number of detected lung nodules and masses during routine care, offering a “second read” in chest X-rays.
An 11,000 patient image retrospective study showed that VisiRad XR spotted lung nodules and masses with 83% sensitivity with a fixed false positives per image rate and fixed operating threshold. IMIDEX said VisiRad XR could help hospitals identify up to an additional 750 lung nodules in a year.
“Achieving this clearance enables us to provide a tool to radiologists that can have a tangible benefit in getting more patients the care they need,” said Richard Vlasimsky, CEO of IMIDEX, “Chest X-rays are the most common radiological procedure in the world, which means that the opportunity for VisiRad XR’s impact is enormous. We’re thrilled to take the next step forward in our mission to save lives lost to lung cancer.”
The software uses machine learning techniques and was developed using global, curated training data. It allows clinicians a closer look at lung lesions that are often overlooked to help identify future lung cancers in outpatient and emergency care settings.
“Radiologists are looking for solutions to help elevate their performance and reduce burnout,” Dr. Raj Chopra, chief medical officer of IMIDEX told the press. “With volumes increasing and staffing decreasing, tools like VisiRad XR are beneficial not only for patient care, but for helping radiologists continue to practice to their full potential.”
The turnkey VisiRad XR tool plugs into current radiology workflows, routing images with AI-detected lesions back to radiologists in their native viewing environment. Results can be seen directly behind the image for interpretation. VisiRad XR’s aim is to increase the number of detected lung nodules and masses during routine care, offering a “second read” in chest X-rays.
An 11,000 patient image retrospective study showed that VisiRad XR spotted lung nodules and masses with 83% sensitivity with a fixed false positives per image rate and fixed operating threshold. IMIDEX said VisiRad XR could help hospitals identify up to an additional 750 lung nodules in a year.
“Achieving this clearance enables us to provide a tool to radiologists that can have a tangible benefit in getting more patients the care they need,” said Richard Vlasimsky, CEO of IMIDEX, “Chest X-rays are the most common radiological procedure in the world, which means that the opportunity for VisiRad XR’s impact is enormous. We’re thrilled to take the next step forward in our mission to save lives lost to lung cancer.”